| F | axed prescriptions will only be | | ted from a prescriber. Patients | must bring an original | prescrip | otion to the ph | narmacy, and car | not fax these re | eferral forms to S | enderra. | | |
|--|---|--|--|------------------------|----------|-----------------|------------------|------------------|--------------------|-----------|---------|--|
| | | Er | soriatic Arthritis Prollment Form | Prescriber: | | NPI: | | | | | | |
| | | A- | п | Supervising Physician: | | | | | NPI: | | | |
| SEND | ERRA | | nysician Offices Call: 5-460-7928 | Address: | | | | | Tax ID: | | | |
| Specialty Pharmacy Fa 3712 E. Plano Parkway, Ste. 200 | | x: 888-777-5645 | Phone: | | | | Fax: | · | | | | |
| Plano, TX 75074 This prescription form | is to be sent & received via fax | | | Contact: | | | | | | | | |
| | | | ı | PATIENT INFOR | MATI | ON | | | | | | |
| Name: | | | □ M □ F □ Trans M □ Trans F □ Other DOB: | | | | / / | SS#: | | | | |
| Street: | | | City: | | | State: | | | ZIP: | | | |
| Phone: Alt. Ph | | | hone: | | | | Other: _ | | Wt.: | Ht.: | | |
| PRESCRIPTION | | | | | | | | | | | | |
| Has the patient received a loading dose/starter kit? Yes Start Date: No SHIP TO: Patient's Home Doctor's Office Other: | | | | | | | | | | | | |
| Drug | | | Directions & Quantity | | | | | | | | Refills | |
| | □ Pre-filled Syringe □ Autoinjector | | ☐ INITIAL: Inject 320 mg SQ at week 0, 4, 8, 12, and 16 (Quantity: 5) ***Intended for patients | | | | | | | | | |
| Bimzelx [®] | | | ☐ MAINTENANCE: Inject 320 mg SQ every 8 weeks (Quantity: 1) With coexistent moderate-to-severe plaque to-severe plaque psoriasis*** | | | | | | | | | |
| | | | patients ≥ 120 kg (264 lbs)*** ☐ Inject 160 mg SQ every 4 weeks (Quantity: 1) | | | | | | | | | |
| Cimzia [®] | ☐ Pre-filled Syringe☐ Vials | ☐ INITIAL: Inject 400 mg SQ at Day 0, Day 14, and Day 28 (Quantity: 6) ☐ MAINTENANCE: Inject 400 mg SQ every 4 weeks (Quantity: 2) ☐ MAINTENANCE: Inject 200 mg SQ every 2 weeks (Quantity: 2) | | | | | | | | | | |
| Cosentyx [®] | ☐ Sensoready® Pen☐ Pre-filled Syringe | | ☐ INITIAL: Inject 150 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: 5) ☐ MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1) | | | | | | | | | |
| | Sensoready® Pen UnoReady® Pen Pre-filled Syringe UnoReady® Pen Refilled Syringe UnoReady® Pen National Inject 300 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: QS 5 doses) National Inject 300 mg SQ every 4 weeks (Quantity: QS 28 days) | | | | | | | | | | | |
| Enbrel® | ☐ SureClick® Pen☐ Mini® with AutoTou☐ Pre-filled Syringe | ıch® | ☐ Inject 50 mg SQ every week (Quantity: 4) | | | | | | | | | |
| Humira® Citrate Free | Pen Inject 40 mg SQ every other week (Quantity: 2) | | | | | | | | | | | |
| | , - | | | EDICAL INFOR | | | | | | | | |
| ***PLEASE F | AX COPY OF PRESC | | ION/MEDICAL CARD, | | CK, A | S WELL | AS ANY CLI | NICAL NOT | res regar | DING THER | APY*** | |
| | JS THERAPIES: | | Tried & Failed (Dura | ition): No | t Tole | erated: | | Cor | ntraindicat | ion: | | |
| □ Methotrexate □ | | | (|) | | | | | | | | |
| □ Plaquenil □ | | | (|) | | | | | | | | |
| □ Enbrel □ | | | (|) | | | | | | | | |
| <u> </u> | | (|) | | | | | | | | | |
| □ | | | | | | | | | | | | |
| □ L40.59 Other Psoriatic Arthropathy □ Other: | | | | | | | | | | | | |
| Date of Diagr | nosis:/_ | /_ | Alle | ergies: | | | | | | | _ | |
| Active TB is ruled out: Yes No Date:// Hep B ruled out/treated: Yes No Date:// | | | | | | | | | | | | |
| Additional Cl | inical Information: | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | INJECTION TRA | AININ | IG | | | | | | |
| □ Patient has received pen and injection training □ Physician's office to provide injection training □ Senderra to coordinate injection training | | | | | | | | | | | | |
| PRESCRIBER SIGNATURE To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription | | | | | | | | | | | | |
| insurance companies, and co-pay assistance foundati Prescriber: | | | tions. | | | | | Date: | | | | |
| | | | CONFIDENTIALITY MOTIOE | | | | | | / | / | | |
| CONFIDENTIALITY NOTICE IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are | | | | | | | | | | | | |
| | not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately. | | | | | | | | | | | |

Psoriatic Arthritis Enrollment (Rev. 1/21/2025)